跳至主要内容
临床试验/NCT07356609
NCT07356609尚未招募不适用

Primary Care ERectile Function Outcome Registry for Men

Nabiqasim Industries (Pvt) Ltd0 个研究点目标入组 255 人开始时间: 2026年2月6日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
255

研究概览

简要总结

The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Adult male above 18 years of age
  • •Patient reports erectile dysfunction (symptomatic).
  • •Patient is eligible to be prescribed sildenafil by treating clinician.

排除标准

  • •If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)
  • •Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication
  • •Recent or unstable cardiovascular disease
  • •Myocardial infarction or stroke in last 3 months
  • •Unstable angina
  • •Uncontrolled arrhythmia or heart failure NYHA III-IV
  • •Resting hypotension (SBP < 90 mmHg) or uncontrolled hypertension (SBP > 180 mmHg) per treating clinician
  • •Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe)
  • •Known hypersensitivity to sildenafil or excipients
  • •Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan/dose adjustment

研究者

申办方类型
Industry
责任方
Sponsor

相似试验